The global C-reactive protein testing market revenue was around US$ 2,765.07 million in 2021 and is estimated to reach US$ 3,588.9 million by 2030, growing at a compound annual growth rate (CAGR) of 2 ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming ...

US FDA clears Lomond Therapeutics’ IND application for phase 1 multicenter study of lonitoclax in patients with relapsed/refractory AML: Dover, Delaware Monday, June 23, 2025, 1 ...

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Detailed price information for Aptevo Therapeutics Inc (APVO-Q) from The Globe and Mail including charting and trades.

Despite longstanding reliance on sputum smear microscopy, culture methods, and chest X-rays, conventional TB diagnostics ...

AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed among ...